Human Health Division (HHD) Products
Product List by Generic Name
Ospemifene
Composition
Osmina Tablet: Each film coated tablet contains Ospemifene INN 60 mg.
Indication
Osmina is an estrogen agonist/antagonist indicated for the treatment of moderate to severe dyspareunia & vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.
Dosage & Administration
Osmina is an estrogen agonist/antagonist which has agonistic effects on the endometrium. Use of Osmina should be for the shortest duration consistent with treatment goals and risks for the individual women. One tablet should be taken orally once daily with food or as directed by the physician.
Olmesartan + Amlodipine
Composition
Olmepin™ 20/5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Olmepin™ 40/5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 40 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Indication
Olmepin™ is indicated for the treatment of hypertension, alone or with other antihypertensive agents.
Olmepin™ may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Dose & Administration:
Initial Therapy: The usual starting dose of Olmesartan Medoxomil/Amlodipine Besilate is 20/5 mg
one tablet once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum dose of 40/10 mg once daily as needed to control blood pressure. This combination may be taken with or without food. This combination may be administered with other antihypertensive agents.
Initial therapy with this combination products is not recommended in patients >75 years old or with hepatic impairment.
Replacement therapy: Olmesartan Medoxomil/Amlodipine Besilate may be substituted for its individually titrated components. When substituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory.
Add-on Therapy: Olmesartan Medoxomil/Amlodipine Besilate may be used to provide additional blood pressure lowering for patients not adequately controlled with Amlodipine (or another dihydropyridine Calcium Channel Blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone or as directed by the physician.
Ozenoxacin
Composition:
Zenocin Cream: Each gram cream contains Ozenoxacin INN 10 mg.
Indication:
Zenocin Cream is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and paediatric patients 2 months of age and older.
Dose & Administration:
Apply a thin layer of Zenocin cream topically to the affected area twice daily for five days or as directed by the physicians.
Omeprazole
Composition
Ometac® 20: Each capsule contains Omeprazole BP 20 mg.
Indications:
Ometac®is indicated for the treatment of gastroesophageal reflux disease including reflux esophagitis, acid reflux disease, duodenal and benign gastric ulcers, Helicobacter pylori eradication in peptic ulcer disease, prophylaxis of acid aspiration, Zollinger-Ellison Syndrome and for the treatment of NSAID-associated gastric ulcers, duodenal ulcers or gastroduodenal erosions.
Dosage & Administration:
Reflux esophagitis: The usual dose is 20 mg once daily for 4 weeks or as directed by the physician.
Zollinger-Ellison Syndrome: Recommended initial dose is 60 mg once daily which is to be adjusted individually. Doses above 80 mg should be given in two divided doses.
Duodenal & Benign Gastric Ulcer: The usual dose is 20 mg once daily. The majority of patients with duodenal ulcer are healed after 4 weeks. For gastric ulcer, the treatment should be continued up to 8 weeks.
Elderly: No doses adjustment is required.
Children: No experience in using the drug in children.
Olmesartan + Hydrochlorothiazide
Composition:
Olmeben™ Plus 20/12.5 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Hydrochlorothiazide BP 12.5 mg
Indication:
It is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.
Dose & Administration:
Hypertension
The usual starting dose of Olmeben™ Plus 20/12.5 is one tablet once daily. Dosing should be
individualized. Depending on the blood pressure response, the dose may be titrated at intervals of
2-4 weeks.
Patients with Renal Impairment:
The usual regimens of therapy with Olmeben™ Plus 20/12.5 may be followed provided the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, Olmeben™ Plus 20/12.5 is not recommended. Patients with Hepatic Impairment: No dosage adjustment is necessary with hepatic impairment.
Or as directed by the physician.
Olmesartan
Composition:
Olmeben™ 20 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 20 mg.
Olmeben™ 40 Tablet: Each film coated tablet contains Olmesartan Medoxomil USP 40 mg.
Indication:
It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Dose & Administration:
The usual starting dose of Olmesartan is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. Olmesartan may be administered with or without food. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 ml/min) or with moderate to marked hepatic dysfunction. If blood pressure is not controlled by Olmesartan alone, a diuretic may be added. Olmsartan may be administerd with other antihypertensive agents. Or as directed by the physician.
Olopatadine
Composition:
Alleloc DS Sterile Eye Drops: Each ml drops contains Olopatadine Hydrochloride USP equivalent to Olopatadine 2 mg.
Indications:
Allergic conjunctivitis.
Dosage and administration:
Alleloc DS: Instill one drop in the affected eye (s) once daily or as directed by the physician.
